Zofran Lawsuit Alleges Drug Maker Knew About The Birth Defects Risk Associated With Anti-Nausea Medication During

Print

Zofran Lawsuit Claims Against GlaxoSmithKline Contend The Company Knew About The Birth Defects Associated With Zofran, Including Congenital Heart Disease, Kidney Malformations, And Intrauterine Death, But Failed To Inform Pregnant Mothers And Their Physicians About The Riskss.

Zofran-Birth-Defects-Lawsuit-Wright-and-Schulte-LLCThe attorneys at Wright & Schulte LLC, continue to represent clients in birth-defect lawsuits and report a recent filing of a Zofran lawsuit by a Montana woman, who took the anti-nausea medication Zofran to treat morning sickness and later gave birth to a child born with a cleft lip and palate. According to the Zofran complaint, the child was born in 1988, but it wasn’t until February 2015 that the parents learned the birth defects were allegedly the result of prenatal exposure to Zofran. The Zofran birth-defects lawsuit claims that the child had to under 10 surgeries, including one in January 2015, in an attempt to correct her cleft lip and palate because the birth defect impairs her development and enjoyment of a normal life at home and at school. The Zofran lawsuit purports that Zofran’s manufacturer, GlaxoSmithKline knew about the birth defect risks but failed to disclose this information to physicians and pregnant women. The Zofran birth-defects lawsuits claims that had the plaintiff “known the truth” about the anti-nausea medication’s “unreasonable risk” of harm, she would not have taken Zofran and her child would not have been injured. (Case No. 1:15-cv-00026, U.S. District Court, District of Montana)

“The Zofran birth defects lawsuits share common allegations that women who took Zofran to treat morning sickness during their first trimester of pregnancy gave birth to children with congenital malformations,” says Wright & Schulte LLC, a law firm that aggressively represents families whose children have been injured by defective drugs. “This has become a problem nationwide and will continue to investigate and monitor the allegations surrounding this anti-nausea medication”

Zofran was approved by the U.S. Food and Drug Administration (FDA) in 1991 to treat post-operative nausea and vomiting as well as severe nausea in seriously ill patients undergoing chemotherapy or radiation, according to court documents. The Zofran lawsuits contend that Zofran’s manufacturer, GlaxoSmithKline marketed the anti-nausea medication “off-label” to treat pregnancy-induced nausea and vomiting, also known as morning sickness. The Zofran lawsuit claims accuse GlaxoSmithKline of not conducting “a single study” on the effects of Zofran on a pregnant woman and her child. The Zofran complaint asserts that the manufacturer chose not to undergo a clinical trial or seek approval from the FDA to market the anti-nausea medication to pregnant women. According to the Zofran claims, GlaxoSmithKline did not conduct trials because it would “have hampered its marketing” of the prescription drug and “decrease profits” by associating the drug with serious birth defects.

According to court documents, GlaxoSmithKline began receiving reports linking Zofran to birth defects in 1992. By 2000, the company had received at least 32 reports of birth defects linked with Zofran use, the court records indicate. The complaints allege that the birth defects include congenital heart disease, intrauterine death, orofacial anomalies (relating to the face and mouth), kidney malformations and stillbirth. Court documents indicate that GlaxoSmithKline has received over 200 more reports of birth defects, to date. The Zofran complaints assert that scientists have conducted “large-scale epidemiological studies” that showed an elevated risk of birth defects developing in babies whose mothers took the medication during pregnancy. However, GlaxoSmithKline did not disclose these findings to pregnant women or their physicians, according to the complaints.

Court documents indicate that GlaxoSmithKline pleaded guilty in July 2012 to criminal charges brought by the U.S. Department of Justice for promoting its drugs, including Zofran, for uses not approved by the FDA. Additionally, the court documents say that GlaxoSmithKline also paid $1 billion to settle civil complaints that the company illegally marketed its various drugs, including Zofran. According to the complaints, GlaxoSmithKline was accused of the “off label” marketing of Zofran to treat morning sickness in pregnant women and offering kickbacks to health care professionals who promoted and prescribed Zofran.

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Zofran lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

This entry was posted in Wright & Schulte Lawsuit News. Bookmark the permalink.